Imeglimin is an oral anti-diabetic medication approved for use in Japan in June 2021. It is a pharmaceutical raw material used in the manufacture of finished dosage forms.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 775351-65-0
Imeglimin hydrochloride
pharmaceutical raw material
Potassium bromide
pharmaceutical raw material
Thymosin beta 4 acetate
pharmaceutical raw material
Trimagnesium dicitrate
pharmaceutical raw material
Tin(II) fluoride
pharmaceutical raw material
Imeglimin (hydrochloride)
pharmaceutical raw material
(4R)-6-N,6-N,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine
GFICWFZTBXUVIG-SCSAIBSYSA-N
C[C@@H]1N=C(NC(=N1)N(C)C)N